- Home
- BBW vs CELC Comparison
BBW vs CELC Comparison
Compare BBW & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBW
- CELC
- Stock Information
- Founded
- BBW 1997
- CELC 2011
- Country
- BBW United States
- CELC United States
- Employees
- BBW N/A
- CELC N/A
- Industry
- BBW Recreational Games/Products/Toys
- CELC Medical Specialities
- Sector
- BBW Consumer Discretionary
- CELC Health Care
- Exchange
- BBW Nasdaq
- CELC Nasdaq
- Market Cap
- BBW 464.1M
- CELC 440.0M
- IPO Year
- BBW 2004
- CELC 2017
- Fundamental
- Price
- BBW $52.94
- CELC $12.33
- Analyst Decision
- BBW Strong Buy
- CELC Strong Buy
- Analyst Count
- BBW 4
- CELC 5
- Target Price
- BBW $53.00
- CELC $30.80
- AVG Volume (30 Days)
- BBW 296.1K
- CELC 131.2K
- Earning Date
- BBW 05-29-2025
- CELC 08-13-2025
- Dividend Yield
- BBW 1.67%
- CELC N/A
- EPS Growth
- BBW 19.03
- CELC N/A
- EPS
- BBW 4.15
- CELC N/A
- Revenue
- BBW $510,069,000.00
- CELC N/A
- Revenue This Year
- BBW $5.60
- CELC N/A
- Revenue Next Year
- BBW $3.65
- CELC N/A
- P/E Ratio
- BBW $12.67
- CELC N/A
- Revenue Growth
- BBW 6.09
- CELC N/A
- 52 Week Low
- BBW $23.63
- CELC $7.58
- 52 Week High
- BBW $55.57
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- BBW 69.61
- CELC 53.67
- Support Level
- BBW $47.70
- CELC $11.85
- Resistance Level
- BBW $53.56
- CELC $13.40
- Average True Range (ATR)
- BBW 1.82
- CELC 0.64
- MACD
- BBW 0.27
- CELC -0.04
- Stochastic Oscillator
- BBW 87.04
- CELC 48.79
About BBW Build-A-Bear Workshop Inc.
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.